Podcast: Play in new window | Download (Duration: 6:09 — 10.7MB)

Subscribe: Apple Podcasts | Android | Email | RSS

The FDA’s approval of the abortion-inducing medication Mifepristone is at the center of numerous court rulings this month. The U.S. Supreme Court has put on hold a recent ruling by a federal judge in the Northern District of Texas. He invalidated the Food and Drug Administration’s approval of Mifepristone, which has been part of a two-drug regimen typically used for medication abortions and miscarriage management for more than 20 years. However the federal agency has reduced their restrictions on the drug in the past few years.

The Alliance for Hippocratic Medicine contends that the use-at-home pills can be dangerous for pregnant women, to say nothing of its impact on the fetus. As the nation awaits the latest ruling from the high court, Family Life’s Abigail Hofland speaks with two pro-life guests — and provides related comments from New York’s governor Kathy Hochul.

• Tessa Longbons of the Charlotte Lozier Institute talks about the medical statistics related to Mifepristone, which is now distributed by mail, without women meeting in person with a physician. Longbons says the FDA has missed about 50% of reports of complications. The number of emergency room visits have multiplied times six, since the initial FDA approval.
• Emily Cappello of Feminists Choosing Life of New York says the push for abortion puts today’s prominent feminists against the realities of women’s empowerment. Cappello says Covid-era changes which allow prescribing doctors from authorizing the pills without seeing the patient first puts women at more frequent risk. Follow-up mental health evaluations, she says, are crucial.

A Supreme Court decision on approval or limits on the drug is scheduled for no sooner than Friday, April 21.